

1. Zhang W, Doherty M, Bardin T, et al. EULAR recommendations for calcium pyrophosphate crystal associated arthritis. Part I: Terminology and diagnosis. *Ann Rheum Dis* 2010 .
2. Zhang W, Doherty M, Bardin T, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 2006 ; 65 : 1312 – 24 .
3. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage* 2008 ; 16 : 137 – 62 .
4. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of
03_annrheumdis139360.indd 574 3/2/2011 1:08:15 AM
Downloaded from ard.bmj.com on July 10, 2014 - Published by group.bmj.com
Recommendation
Ann Rheum Dis 2011;70:571–575. doi:10.1136/ard.2010.139360 575
recommendations endorsed by the EULAR standing committees. *Ann Rheum Dis* 2004 ; 63 : 1172 – 6 .
5. Shekelle PG, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. *BMJ* 1999 ; 318 : 593 – 6 .
6. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. Hillsdale, NJ: Lawrence Erlbaum Associates 1988 .
7. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. *BMJ* 1995 ; 310 : 452 – 4 .
8. Kleinbaum DG, Kuppler LL, Morgenstern H. *Epidemiologic Research – Principles and Quantitative Methods*. Chichester, UK: John Wiley & Sons, Inc, 1982 .
9. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 2005 ; 64 : 669 – 81 .
10. Roddy E, Zhang W, Doherty M, et al. Evidence-based clinical guidelines: a new system to better determine true strength of recommendation. *J Eval Clin Pract* 2006 ; 12 : 347 – 52 .

11. Doherty M, Dieppe PA. Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee. *Lancet* 1981 ; 2 : 1243 – 6 .
12. Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. *Compr Ther* 1997 ; 23 : 327 – 31 .
13. Das SK, Mishra K, Ramakrishnan S, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. *Osteoarthritis Cartilage* 2002 ; 10 : 247 – 52 .
14. Maldonado MA, Salzman A, Varga J. Intravenous colchicine use in crystal-induced arthropathies: a retrospective analysis of hospitalized patients. *Clin Exp Rheumatol* 1997 ; 15 : 487 – 92 .
15. Spilberg I, Berney S. Colchicine and pseudogout. *Arthritis Rheum* 1979 ; 22 : 427 – 8 .
16. Tabatabai MR, Cummings NA. Intravenous colchicine in the treatment of acute pseudogout. *Arthritis Rheum* 1980 ; 23 : 370 – 4 .
17. Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. *J Rheumatol* 1994 ; 21 : 696 – 9 .
18. Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. *Rev Rhum Engl Ed* 1996 ; 63 : 248 – 54 .
19. Roane DW, Harris MD, Carpenter MT, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. *J Rheumatol* 1997 ; 24 : 1168 – 70 .
20. Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. *J Rheumatol* 1986 ; 13 : 804 – 5 .
21. Chollet-Janin A, Finckh A, Dudler J, et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. *Arthritis Rheum* 2007 ; 56 : 688 – 92 .
22. Trostle D, Schumacher HR. Probenecid therapy of refractory CPPD deposition disease. *Arthritis Rheum* 1999 ; 42 : 539 .
23. Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. *Ann Rheum Dis* 1983 ; 42 : 106 – 7 .
24. Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis

in the elderly and its association with knee osteoarthritis: the Framingham Study.

J Rheumatol 1989 ; 16 : 1241 – 5 .

25. Neame RL, Carr AJ, Muir K, et al. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis 2003 ; 62 : 513 – 18 .

26. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence.

Osteoarthr Cartil 2007 ; 15 : 981 – 1000 .

27. Landewe RB, Gunther KP, Lukas C, et al. EULAR/EFORT Recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. Ann Rheum Dis 2010 ; 69 : 12 – 19 .

28. Schlesinger N, Detry MA, Holland BK, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002 ; 29 : 331 – 4 .

29. Schlesinger N. Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol 2006 ; 12 : 275 – 6 .

30. Cardone DA, Tallia AF. Joint and soft tissue injection. Am Fam Physician 2002 ; 66 : 283 – 8 .

31. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987 ; 17 : 301 – 4 .

32. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009.

Osteoarthr Cartil 2010 ; 18 : 476 – 99 .

33. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003 ; 62 : 1145 – 55 .

34. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Ann Rheum Dis 2007 ; 66 : 377 – 88 .

35. National Collaborating Centre for Chronic Conditions. Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians, 2008 .
36. Doherty M, Dieppe P, Watt I. Pyrophosphate arthropathy: a prospective study. *Br J Rheumatol* 1993 ; 32 : 189 – 96 .
37. Ledingham J, Regan M, Jones A, et al. Factors affecting radiographic progression of knee osteoarthritis. *Ann Rheum Dis* 1995 ; 54 : 53 – 8 .
38. Reichenbach S, Blank S, Rutjes AW, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. *Arthritis Rheum* 2007 ; 57 : 1410 – 18 .
39. Torres R, Macdonald L, Croll SD, et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. *Ann Rheum Dis* 2009 ; 68 : 1602 – 8 .
40. Terkeltaub R, Sundry JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. *Ann Rheum Dis* 2009 ; 68 : 1613 – 17 .
41. White JC, Brandt FB, Geelhoed GW. Acute pseudogout following parathyroidectomy. *Am Surg* 1988 ; 54 : 506 – 9 .
42. Geelhoed GW, Kelly TR. Pseudogout as a clue and complication in primary hyperparathyroidism. *Surgery* 1989 ; 106 : 1036 – 41 , discussion 1041–2.
43. Tavill AS. American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. Diagnosis and management of hemochromatosis. *Hepatology* 2001 ; 33 : 1321 – 8 .
44. AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. *Endocrine Practice* 2005 ; 11 : 49 – 54 .
45. Cheng PT, Pritzker KP. The effect of calcium and magnesium ions on calcium pyrophosphate crystal formation in aqueous solutions. *J Rheumatol* 1981 ; 8 : 772 – 82 .
46. Bennett RM, Lehr JR, McCarty DJ. Crystal shedding and acute pseudogout. An hypothesis based on a therapeutic failure. *Arthritis Rheum* 1976 ; 19 : 93 – 7 .

47. Runeberg L, Collan Y, Jokinen EJ, et al. Hypomagnesemia due to renal disease of unknown etiology. *Am J Med* 1975 ; 59 : 873 – 81 .
48. Ho AH, Johson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. *Science* 2000 ; 289 : 165 – 70 .
49. Cini R, Chindamo D, Catenaccio M, et al. Dissolution of calcium pyrophosphate crystals by polyphosphates: an in vitro and ex vivo study. *Ann Rheum Dis* 2001 ; 60 : 962 – 7 .
50. Wierzbicki A, Cheung HS. Molecular modeling of inhibition of crystals of calcium pyrophosphate dihydrate by phosphocitrate. *J Mol Struct (Theochem)* 1998 ; 454 : 287 – 97 .
51. Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. *Clin Exp Rheumatol* 2005 ; 23 : 819 – 28 .